ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

On May 27, 2025 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that management will participate in the following investor conferences in June (Press release, ORIC Pharmaceuticals, MAY 27, 2025, View Source [SID1234653401]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 4, 2025, at 12:50 p.m. ET
Goldman Sachs 46th Annual Global Healthcare Conference – Participating in a fireside chat on Tuesday, June 10, 2025, at 10:00 a.m. ET

Webcasts of the discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the event.

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

On May 27, 2025 Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, "ImmuneOnco"), reported clinical trial updates of ‘2510 and NSCLC clinical development strategy (Press release, Instil Bio, MAY 27, 2025, View Source [SID1234653400]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted with the significant clinical advancements by our collaborator, ImmuneOnco, with ‘2510 for NSCLC in China," said Bronson Crouch, CEO of Instil. "We are confident that ‘2510 has the potential to emerge as a leading PD-(L)1xVEGF bispecific antibody, and we look forward to the initial results from the ongoing first-line chemotherapy combination trial in China. In parallel, we are advancing preparations to initiate U.S. clinical development later this year, and we look forward to bringing this potential important new medicine to patients globally."

Dr. Tian Wenzhi, CEO of ImmuneOnco, said, "Our collaboration on ‘2510 has achieved meaningful progress. We are actively conducting a Phase 2 clinical trial of ‘2510 in combination with chemotherapy in patients with first-line NSCLC. The data generated to date underscore its best-in-class potential within the promising PD-(L)1xVEGF class. We anticipate sharing further clinical data in the second half of 2025."

Phase 2 Trial of ‘2510 in Combination with Chemotherapy in First-line NSCLC
•ImmuneOnco expects to complete enrollment of approximately 60 patients in Q3 2025 in its Phase 2 trial of ‘2510 in combination with chemotherapy in patients with NSCLC in the first-line setting in China.
•Among more than 30 NSCLC patients enrolled (including the safety run-in), more than 20 first-line NSCLC patients have been treated since the end of March.
•ImmuneOnco anticipates sharing initial safety and efficacy results from this Phase 2 trial in the second half of 2025.

‘2510 Monotherapy Data in Relapsed/Refractory NSCLC (China)
•The objective response rate (ORR) is similar to datasets from competitor PD-(L)1xVEGF bispecific antibodies at a similar stage of development in patients with previously treated NSCLC, showing ORR of 23% (efficacy evaluable n=13).
•The updated clinical safety from the full ‘2510 monotherapy trial (n=106) and efficacy data in NSCLC are further detailed in a new corporate deck posted on Instil Bio’s investor relations webpage at View Source

Other ‘2510 Clinical and Preclinical Updates
•Instil’s Phase 1b/2 trial of ‘2510 in the United States is expected to be initiated before the end of 2025, assuming the necessary regulatory approvals are obtained. The trial is expected to be a monotherapy dose optimization trial in relapsed/refractory solid tumors, which is intended to bridge the doses to the ongoing China trials and replaces the previously planned US ‘2510 and chemotherapy combination trial in first-line NSCLC.
◦Instil believes that this change may accelerate the path to initiating a potential global Phase 3 trial in first-line NSCLC.

•Preclinical assays demonstrate cooperative binding of ‘2510 to PD-L1 in the presence of VEGF in vitro. Further preclinical datasets demonstrating the unique and potentially best-in-class mechanism of action of ‘2510 are anticipated to be presented at future medical or scientific conferences.

About AXN-2510
AXN-2510 is a PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. AXN-2510/IMM2510 is differentiated from other PD-(L)1xVEGF bispecific antibodies by its VEGF trap, which binds multiple VEGF receptor ligands beyond VEGF-A, a bispecific structure which leverages PD-L1 as an anchor in the tumor microenvironment (TME), and enhanced antibody-dependent cellular cytotoxicity (ADCC) to direct killing of PD-L1-positive tumor cells.

INNATE PHARMA ANNOUNCES ITS PARTICIPATION IN JEFFERIES AND GOLDMAN SACHS HEALTHCARE CONFERENCES

On May 27, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that members of its executive team will present and host 1×1 meetings at the upcoming investor conferences, detailed below (Press release, Innate Pharma, MAY 27, 2025, View Source [SID1234653399]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

•Jefferies Global Healthcare Conference
Dates: June 3 – 5 2025 | New-York, USA

The executive team will participate in a fireside chat scheduled on Thursday June 5, 2025, from 7:35 to 8:05 am EDT.

•Goldman Sachs 46th Annual Global Healthcare Conference
Dates: June 9 – 11 2025 | Miami, USA

The executive team will participate in a fireside chat scheduled on Tuesday June 10 2025, from 4:00 to 4:35 pm EDT.

In addition, members of the executive team will participate and represent the Company during the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held from May 30 to June 3, 2025 in Chicago, Illinois.

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

On May 27, 2025 IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, reported that an abstract highlighting IMNN-001 data based on an immune biomarker analysis from the Phase 2 OVATION 2 Study in women with newly diagnosed advanced ovarian cancer was accepted for poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Gynaecological Cancers Congress 2025, being held June 19-21, 2025 in Vienna, Austria (Press release, IMUNON, MAY 27, 2025, View Source [SID1234653398]). The abstract, titled "Immune biomarker analysis of the OVATION-2 trial, a randomized Phase I/II study of IL-12 gene therapy IMNN-001 in combination with Neo/Adjuvant Chemotherapy (NACT) in newly-diagnosed advanced Epithelial Ovarian Cancer (EOC)," will be presented by Premal H. Thaker, M.D., Interim Chief of Gynecologic Oncology, David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology, Director of Gynecologic Oncology Clinical Research at Washington University School of Medicine, OVATION 2 Study Chair and Study Chair of the Phase 3 OVATION 3 trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMUNON also recently announced that new positive data from the OVATION 2 Study will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and simultaneously published in the peer-reviewed journal Gynecologic Oncology. Results include continuous clinically significant improvement in the IMNN-001 treatment group, with median 13-month and 3-month increases in overall and progression-free survival, respectively.

IMNN-001, based on IMUNON’s proprietary TheraPlas technology platform, is an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, enabling cell transfection followed by persistent, local production and secretion of the IL-12 protein in the tumor microenvironment. IL-12 is a powerful pluripotent cytokine known for inducing strong anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation while inhibiting tumor-mediated immune suppression. IMNN-001 is the first and only IL-12 immunotherapy to achieve a clinically effective response including overall survival benefit in frontline treatment in patients with advanced (stage III/IV) ovarian cancer.

"We are very pleased to be invited to present OVATION 2 biomarker analysis data at ESMO (Free ESMO Whitepaper)’s Gynaecological Cancers Congress, especially in light of the remarkable IMNN-001 survival data that we reported from the study, which are being presented at the ASCO (Free ASCO Whitepaper) Annual Meeting and in the journal Gynecologic Oncology," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. "It is highly encouraging to see the global scientific community’s strong interest in our promising and novel IMNN-001 immunotherapy including enthusiasm from leading researchers from the European Union and Latin America in participating in our pivotal Phase 3 trial. There is a significant opportunity to improve the standard of care for thousands of women diagnosed with advanced ovarian cancer, and we look forward to advancing this program in our Phase 3 trial and positioning IMNN-001 for regulatory review in the European Union and markets around the world."

The pivotal Phase 3 OVATION 3 Study of IMNN-001 will include women with newly diagnosed advanced ovarian cancer (stage IIIC or IV) who are eligible for neoadjuvant and adjuvant chemotherapy (N/ACT) (the ITT population), with a sub-group of HRD+ women including those with BRCA1 or BRCA2 mutations. Study participants will be randomized 1:1 to receive either IMNN-001 plus standard of care N/ACT or standard of care N/ACT alone. The primary endpoint of the study is overall survival, and secondary endpoints are surgical response score, chemotherapy response score, clinical response and time to second-line treatment. The study will also assess several exploratory endpoints. IMUNON recently initiated the first two sites for the OVATION 3 Study.

About the Phase 2 OVATION 2 Study

OVATION 2 evaluated the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. Following N/ACT, patients undergo interval debulking surgery, followed by three additional cycles of adjuvant chemotherapy to treat any residual tumor. This open-label study enrolled 112 patients who were randomized 1:1 and evaluated for safety and efficacy to compare N/ACT plus IMNN-001 versus standard-of-care N/ACT. In accordance with the study protocol, patients randomized to the IMNN-001 treatment arm could receive up to 17 weekly doses of 100 mg/m2 in addition to N/ACT. As a Phase 2 study, OVATION 2 was not powered for statistical significance. Additional endpoints included objective response rate, chemotherapy response score and surgical response.

About IMNN-001 Immunotherapy

Designed using IMUNON’s proprietary TheraPlas platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.

About Epithelial Ovarian Cancer

Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year and approximately 70% are diagnosed in advanced Stage III/IV. Epithelial ovarian cancer is characterized by dissemination of tumors in the peritoneal cavity with a high risk of recurrence (75%, Stage III/IV) after surgery and chemotherapy. Since the five-year survival rates of patients with Stage III/IV disease at diagnosis are poor (41% and 20%, respectively), there remains a need for a therapy that not only reduces the recurrence rate but also improves overall survival. The peritoneal cavity of advanced ovarian cancer patients contains the primary tumor environment and is an attractive target for a regional approach to immune modulation.

GlyTherix & Isotopia Unite to Advance Radiopharmaceutical Innovation

On May 27, 2025 GlyTherix Ltd reported a strategic supply agreement with Isotopia Molecular Imaging Ltd for the provision of Lutetium-177 (Lu-177) and Terbium-161 (Tb-161), key radioisotopes for advancing our targeted radiopharmaceutical therapies (Press release, Glytherix, MAY 27, 2025, View Source [SID1234653397]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This collaboration strengthens our ability to develop innovative cancer treatments and reinforces our commitment to delivering cutting-edge solutions to patients worldwide. Isotopia’s expertise in isotope production ensures a reliable and high-quality supply, supporting GlyTherix’s mission to transform precision oncology.

Together, we are pushing the boundaries of radiopharmaceutical innovation and building the next generation of cancer care.